Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma
1
Department of Hepatology & Gastroenterology, Charité University Medicine Berlin, 13353 Berlin, Germany
2
Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada
3
Department of Pharmacology & Physiology, University of Calgary, Calgary, AB T2N 4N1, Canada
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(4), 730; https://doi.org/10.3390/cancers13040730
Submission received: 21 January 2021
/
Revised: 7 February 2021
/
Accepted: 8 February 2021
/
Published: 10 February 2021
(This article belongs to the Special Issue Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma)
Simple Summary
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease affecting a quarter of the global population and carries the risk of developing malignant liver cancer. Inflammation is considered paramount in the progression of the disease and many different immune cells and pathways have been implicated in the development of NAFLD. Novel techniques in basic immunology have substantially enhanced the possibilities to study inflammation and the heterogeneity of immune cells. Based on recent studies, we provide a review of novel paradigms emerging in steatohepatitis and the development of hepatocellular carcinoma and outline the multifaceted contributions of immunity to advancing NAFLD. End-stage NAFLD with liver cancer has an abysmal prognosis and effective medical therapies are lacking, therefore a better understanding of the disease mechanisms will ultimately help to improve patients’ care.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a rising chronic liver disease and comprises a spectrum from simple steatosis to nonalcoholic steatohepatitis (NASH) to end-stage cirrhosis and risk of hepatocellular carcinoma (HCC). The pathogenesis of NAFLD is multifactorial, but inflammation is considered the key element of disease progression. The liver harbors an abundance of resident immune cells, that in concert with recruited immune cells, orchestrate steatohepatitis. While inflammatory processes drive fibrosis and disease progression in NASH, fueling the ground for HCC development, immunity also exerts antitumor activities. Furthermore, immunotherapy is a promising new treatment of HCC, warranting a more detailed understanding of inflammatory mechanisms underlying the progression of NASH and transition to HCC. Novel methodologies such as single-cell sequencing, genetic fate mapping, and intravital microscopy have unraveled complex mechanisms behind immune-mediated liver injury. In this review, we highlight some of the emerging paradigms, including macrophage heterogeneity, contributions of nonclassical immune cells, the role of the adaptive immune system, interorgan crosstalk with adipose tissue and gut microbiota. Furthermore, we summarize recent advances in preclinical and clinical studies aimed at modulating the inflammatory cascade and discuss how these novel therapeutic avenues may help in preventing or combating NAFLD-associated HCC.
